secwatch.observer — SEC 8-K summary
======================================

Issuer:     CHEMED CORP (CHE)
CIK:        0000019584
Form:       8-K
Filed at:   2024-10-29T23:59:59+00:00
Accession:  0001562762-24-000241
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Chemed Q3: rev $606M (+7.4%), adj EPS $5.64; FY2024 adj EPS guidance cut to $23.00-$23.15 on Roto-Rooter weakness
--------------------------------------------------------------------------------

- GAAP diluted EPS $5.00 (+1.4%); adjusted diluted EPS $5.64 (+6.0%).
- VITAS net patient revenue $391.4M (+17.3%), ADC 21,785 (+15.5%), adjusted EBITDA $73.1M (+33.1%).
- Roto-Rooter revenue $214.8M (-6.9%), adjusted EBITDA $56.4M (-15.8%), margin 26.3% (-275 bps).
- FY2024 adjusted EPS guidance revised to $23.00-$23.15 (targeting 13.3%-14.0% growth over 2023) due to softer Roto-Rooter results.
- Repurchased 100,000 shares for $57.8M at $578.21/share; cash $238.5M, no debt.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/19584/000156276224000241/0001562762-24-000241-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/19584/000156276224000241/che-20241029x8k.htm
  HTML page:      https://secwatch.observer/filing/0001562762-24-000241

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer